Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A2 | O94788 | 7/20 | 0.60 |
| ▸ | ALDH1A3 | P47895 | 7/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.51 |
| ▸ | TP53 | P04637 | 5/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5433481 | 0.91 | MAPT (0.50) | ALDH1A2ALDH1A3TP53LMNASMN1; SMN2 | |
| SCHEMBL5426673 | 0.89 | TP53 (0.54) | ALDH1A2ALDH1A3TP53LMNASMN1; SMN2 | |
| SCHEMBL5438687 | 0.89 | ALDH1A1 (0.49) | ALDH1A2ALDH1A3ALDH1A1TP53LMNA | |
| SCHEMBL5433462 | 0.88 | TP53 (0.49) | ALDH1A2ALDH1A3TP53LMNASMN1; SMN2 | |
| SCHEMBL5428727 | 0.88 | ALDH1A1 (0.48) | ALDH1A2ALDH1A3ALDH1A1TP53LMNA | |
| SCHEMBL5436106 | 0.86 | TP53 (0.51) | TP53LMNASMN1; SMN2MAPT | |
| SCHEMBL5432200 | 0.82 | MAOA (0.48) | ALDH1A1TP53MAPTPOLB | |
| SCHEMBL5432449 | 0.82 | NPC1 (0.52) | ALDH1A1TP53LMNASMN1; SMN2MAPT | |
| SCHEMBL5429559 | 0.82 | ALDH1A3 (0.59) | ALDH1A2ALDH1A3ALDH1A1TP53LMNA | |
| SCHEMBL5429803 | 0.82 | ALDH1A2 (0.67) | ALDH1A2ALDH1A3ALDH1A1TP53LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070135454-A1 | Bicyclic pyrimidin-4(3h)-ones and analogues and derivatives thereof which modulate the function of the vanilloid-1-receptor(vr1) | BAYLISS TRACY | 2007-06-14 | — | — | US | claimed |
| EP-1687306-A1 | BICYCLIC PYRIMIDIN-4-(3H)-ONES AND ANALOGUES AND DERIVATIVES THEREOF WHICH MODULATE THE FUNCTION OF THE VANILLOID-1 RECEPTOR (VR1) | MERCK SHARP & DOHME LTD. (GB) | 2006-08-09 | — | — | EP | claimed |
| WO-2005049613-A1 | BICYCLIC PYRIMIDIN-4-(3H)-ONES AND ANALOGUES AND DERIVATIVES THEREOF WHICH MODULATE THE FUNCTION OF THE VANILLOID-1 RECEPTOR (VR1) | MERCK SHARP & DOHME LIMITED (GB) | 2005-06-02 | — | — | WO | claimed |
| US-20070135454-A1 | Bicyclic pyrimidin-4(3h)-ones and analogues and derivatives thereof which modulate the function of the vanilloid-1-receptor(vr1) | BAYLISS TRACY | 2007-06-14 | — | — | US | disclosed |
| EP-1687306-A1 | BICYCLIC PYRIMIDIN-4-(3H)-ONES AND ANALOGUES AND DERIVATIVES THEREOF WHICH MODULATE THE FUNCTION OF THE VANILLOID-1 RECEPTOR (VR1) | MERCK SHARP & DOHME LTD. (GB) | 2006-08-09 | — | — | EP | disclosed |
| WO-2005049613-A1 | BICYCLIC PYRIMIDIN-4-(3H)-ONES AND ANALOGUES AND DERIVATIVES THEREOF WHICH MODULATE THE FUNCTION OF THE VANILLOID-1 RECEPTOR (VR1) | MERCK SHARP & DOHME LIMITED (GB) | 2005-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135454-A1 | Bicyclic pyrimidin-4(3h)-ones and analogues and derivatives thereof which modulate the function of the vanilloid-1-receptor(vr1) | TRPV1, TRPV2, TRPV4 | ALDH1A2 1259/4885ALDH1A3 1534/4885ALDH1A1 825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.